statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer IDEAYA Biosciences Announces Selection of...

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO...

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Ideaya Biosciences participates in a conference call with JPMorgan

IDEAYA Biosciences, Inc. (NASDAQ:IDYA  Get Free Report) has been given an average recommendation of Buy by the thirteen analysts that are presently covering the firm...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $40.42 Average PT from Analysts

This price move could indicate a change in the trend, and may be a sell signal for investors...

IDEAYA Biosciences (IDYA, $43) price exceeded its 50-day Moving Average on March 22, 2024

IDEAYA Biosciences (NASDAQ:IDYA  Free Report) had its target price hoisted by Citigroup from $40.00 to $60.00 in a report released on Thursday morning, Benzinga reports. The brokerage...

IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $60.00 at Citigroup

IDEAYA Biosciences, Inc. (NASDAQ:IDYA  Get Free Report) rose 3.3% during trading on Tuesday . The company traded as high as $45.02 and last traded at $45.02. Approximately 44,215 shares...

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 3.3%

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer IDEAYA Announces Clinical Collaboration to Evaluate IDE161...

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer

Latest Ratings for IDYA
 DateFirmActionFromTo Mar 2022StifelUpgradesHoldBuy Sep 2021StifelInitiates Coverage OnHold Aug 2021HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings for IDYA...

Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Volume	486,221.00
52-Wk High	$47.74
52-Wk Low	$18.09

IDYA Ideaya Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals